GMP Cytokines Market Key Players and Opportunities by 2031

TheGMP Cytokines Market size is projected to reach US$ 350.2 million by 2031 from US$ 128.7 million in 2023. The market is expected to register a CAGR of 9.7% in 2023–2031. Technologically advanced GMP cytokines production is likely to remain a key GMP cytokines market trend.

GMP Cytokines Market Analysis

GMP cytokines utility in cancer therapy, use of cytokines as a potential biomarker for neonatal sepsis, and cytokines for stem cell therapy are the most influential factors responsible for market growth. Additionally, research & development (R&D) activities further drives the market growth during 2021-2031. Further, High Grade-GMP- cytokines production and optimization by the manufacturers will provide lucrative market opportunities in the coming years.

GMP Cytokines Market Overview

Cytokines are critically raw materials for T cell and NK cell therapy manufacturing. For example, PeproGMP Cytokines provide safety, purity, and simplified use in ex vivo manufacturing processes. Additionally, MACS GMP Cytokines offer a large variety of highly active and pure cytokines that perfectly meet the requirements for high-quality raw materials intended for cell manufacturing for cell-based therapies. Therefore, innovative product launches of GMP cytokines may act as an influential factor responsible for market growth.

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

GMP Cytokines Market: Strategic Insights

GMP Cytokines Market Drivers and Opportunities

Rising Research & Development (R&D) Activities to Favor Market

Cytokines are used in clinical research, such as clinical cancer therapy. For example, cytokines stimulate the function, survival, and proliferation of Natural Killer (NK) and T Cells that mediate immune response against tumors.  For example, the MACS GMP Cytokine Portfolio offers ex-vivo cell culture in clinical research. Therefore, for rising clinical research for cytokines, manufacturers are developing high standards cytokines. For example, cytokines used for stem cell research should be low-endotoxin, free from microbes, animal products, and potential toxins. Also, cytokines have to be filtered for purity and tested for adequate biological activity. An example of such GMP cytokines is cytokines “T cell and NK cell” produced through ScaleReady manufacturing. GMP cytokines are critical raw materials for manufacturing T cell and NK cell therapy. The aforementioned factors positively influence the market growth of GMP cytokines during 2021-2031.

High Grade-GMP- Cytokines Production and Optimization by the Manufacturers– An Opportunity in GMP Cytokines Market

Currently, cytokines manufacturers are developing effective strategies for high throughput and effective optimization techniques. BioTechne is an example of such a manufacturer focussing on producing autologous T cell therapies targeting solid tumors cancers. The company seeks to develop innovative methods of cytokine supplementation, reduce cytokine waste, improve dose accuracy across lots, and decrease process risk. A feasibility study was done to monitor clinical effectiveness and optimization techniques for cytokines. Additionally, the company is pursuing to deliver process-fit activity for the residual cytokine products, eliminating GMP cytokine waste. Therefore, producing high Grade-GMP with effective process optimization will ultimately lead to a good quality manufacturing practices to deliver effective output will drive the market in the coming years.

GMP Cytokines Market Report Segmentation Analysis

Key segments that contributed to the derivation of the GMP cytokines market analysis are contaminants, technology, and food type.

• Based on Type, the GMP cytokines market is divided into TNF, interleukins, growth factors, and others. The TNF segment held a larger market share in 2023.
• In terms of application, the market is segmented into cell and gene therapy, tissue engineered products, and others. The cell and gene therapy segment dominated the market in 2023.

GMP Cytokines Market Share Analysis by Geography

The geographic scope of the GMP cytokines market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.

The GMP cytokines market in North America is significantly In North America, the GMP cytokines market is currently in the growth phase and experiencing exponential growth. In North America, the US accounts largest share for the GMP cytokines market. Presence of top biotechnology companies and innovative product launches are the most influential growth factors driving the North America region growth positively. Further, Asia Pacific will account highest CAGR for GMP cytokines market during 2021-2031.

The regional trends and factors influencing the GMP Cytokines Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses GMP Cytokines Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

GMP Cytokines Market Report Scope

GMP Cytokines Market Players Density: Understanding Its Impact on Business Dynamics

The GMP Cytokines Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

GMP Cytokines Market News and Recent Developments

The GMP cytokines market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for innovations, business expansion, and strategies:

• In March 2024, Synthekine Inc. an engineered cytokine therapeutics company announced releasing of Phase 1a/1b clinical trials of α/β biased IL-2 partial agonist, STK-012. (Source: Synthekine, Press Release)
• In March 2022, Xenco, a clinical-stage biopharmaceutical company announced developing engineered antibodies and cytokines to treat cancer and autoimmune diseases and are preclinical data presented from XmAb Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022.
• In July 2022, Sandoz announced US Food and Drug Administration (USFDA) for its Supplemental Biologics Licence Application (sBLA) for a high concentration formulation of 100mg/ml (HCF) of its biosimilar "Hyrimoz" (Adalimumab-adaz). The application includes the indications of the reference medicines Humira (adalimumab) not protected by orphan exclusivity, including the rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis arthritis, and other clinical conditions.

GMP Cytokines Market Report Coverage and Deliverables

The “GMP Cytokines Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:

• GMP Cytokines Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• GMP Cytokines Market trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• GMP Cytokines market analysis covering key market trends, Global and regional framework, major players, regulations, and recent market developments
• GMP Cytokines Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles